Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Rieke E AltenXavier MarietteHanns-Martin LorenzMauro GaleazziAlain CantagrelHubert G NüßleinMelanie ChartierYedid ElbezChristiane RauchManuela Le Bars

Published in: RMD open (2017)

NCT02109666; retrospectively registered 8 April 2014.

Keyphrases

rheumatoid arthritis
high dose
rheumatoid arthritis patients
disease activity